Monitoring treatment with biologics in non-infectious uveitis;Monitoring bei Biologikatherapie der nichtinfektiösen Uveitis

Ophthalmologe

Volumn 108, Issue 1, 2011, Pages 21-24

  Barisani Asenbauer, T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Benefit; Drug monitoring; Risk; Safety; Uveitis

Indexed keywords

EID: 78951492294     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2257-x     Document Type: Article

References (29)

1. Askling J, Baecklund E, Granath F et al (2009) Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68: 648-653.
2. Benezra D, Forrester JV, Nussenblatt RB et al (1991) Uveitis scoring system. Springer, Berlin, S 1-13.
3. Bernasconi O, Papadia M, Herbort CP (2010) Sensitivity of laser flare photometry compared to slit-lamp cell evaluation in monitoring anterior chamber inflammation in uveitis. Int Ophthalmol 30(5): 495-500.
4. Coloma PM, Schuemie MJ, Trifirò G et al (2010) on behalf of the EU-ADR consortium. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf [Epub ahead of print].
5. Cunningham ET Jr, Wender JD (2010) Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol 45(4): 352-358.
6. Ferrándiz C, Carrascosa JM, Boada A (2010) A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol 28(1): 81-87.
7. Guex-Crosier Y, Pittet N, Herbort CP (1994) Evaluation of laser flare-cell photometry in the appraisal and management of intraocular inflammation in uveitis. Ophthalmology 101(4): 728-735.
8. Guly CM, Forrester JV (2010) Investigation and management of uveitis. BMJ 341: c4976.
9. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first International Workshop. Am J Ophthalmol 140(3): 509-516.
10. Jap A, Chee SP (2008) Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 19(6): 535-540.
11. Kane S (2010) Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep 12(6): 502-506.
12. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR (2008) Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol 146(6): 813-818. e1.
13. Kempen JH, Gangaputra S, Daniel E et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146(6): 802-812.
14. Kempen JH, Daniel E, Dunn JP et al (2009) Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 339: b2480.
15. Khraishi M (2009) Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 82: 25-32.
16. Ladas JG, Wheeler NC, Morhun PJ et al (2005) Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol 50(1): 27-47.
17. Lee FF, Foster CS (2010) Pharmacotherapy of uveitis. Expert Opin Pharmacother 11(7): 1135-1146.
18. Maca SM, Schiesser AW, Sobala A et al (2010) Distress, depression and coping in HLA-B27-associated anterior uveitis with focus on gender differences. Br J Ophthalmol [Epub ahead of print].
19. Murphy CC, Greiner K, Plskova J et al (2007) Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol 91(2): 154-156.
20. Okada AA (2010) The dream of biologics in uveitis. Arch Ophthalmol 128(5): 632-635.
21. Pleyer U (2005) Intraocular inflammations. A diagnostic and therapeutic challenge. Ophthalmologe 102(4): 325-328.
22. Sandborn WJ (2010) State-of-the-art: immunosuppression and biologic therapy. Dig Dis 28(3): 536-542.
23. Singh JA, Christensen R, Wells GA et al (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 7(4): CD007848.
24. Sugita S, Yamada Y, Mochizuki M (2010) Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol [Epub ahead of print].
25. Szekanecz Z, Szántó S, Szabó Z et al (2010) Biologics - beyond the joints. Autoimmun Rev 9(12): 820-824.
26. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88: 497-502.
27. Tugal-Tutkun I, Herbort CP (2010) Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol 30(5): 453-464.
28. Tugal-Tutkun I, Herbort CP, Khairallah M, Angiography Scoring for Uveitis Working Group (ASUWOG) (2010) Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol 30(5): 539-552.
29. Wiens A, Venson R, Correr CJ et al (2010) Metaanalysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4): 339-353.